2,3-dihydro-1,4-benzodioxin-5-ethanamine | 261633-75-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: 2,3-dihydro-1,4-benzodioxin-5-ethanamine
• 英文别名: 2-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-ethylamine；2-(2,3-Dihydro-1,4-benzodioxin-5-yl)ethylamine；2-(2,3-Dihydro-1,4-benzodioxin-5-yl)ethan-1-amine；2-(2,3-dihydro-1,4-benzodioxin-5-yl)ethanamine
• CAS: 261633-75-4
• 化学式: C₁₀H₁₃NO₂
• mdl: MFCD10032507
• 分子量: 179.219
• InChiKey: NQAKBMINJHHNDM-UHFFFAOYSA-N

物化性质

• 沸点：
  300.1±31.0 °C(Predicted)
• 密度：
  1.157±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,3-dihydro-1,4-benzodioxin-5-ethanamine 、 乙酸酐 生成 S 23219
  参考文献：
  名称：

  Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine

  摘要：

  式(I)中的取代嘧唑嘧啶衍生物，其中Y1、Y2、Y3、Y4代表N或C—，其中至少两个Y1到Y4代表碳原子，R1代表氯或溴，R2到R7代表氢、甲基或乙基等，而R10和R11独立地代表氢或C1-C6烷基。这些衍生物是有效的mGluR5调节剂，并可用于预防急性和慢性神经系统疾病。

  公开号：

  US20080039458A1
• 作为产物：
  描述：

  5-溴甲基-2,3-二氢-1,4-苯并二噁烯 在 lithium aluminium tetrahydride 作用下， 以 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 28.0h， 生成 2,3-dihydro-1,4-benzodioxin-5-ethanamine
  参考文献：
  名称：

  Substituted oxygenated heterocycles and thio-analogues: synthesis and biological evaluation as melatonin ligands

  摘要：

  A new series of substituted oxygenated heterocycles and thio-analogues were synthesized and evaluated as melatonin receptor ligands. The replacement of the indolic moiety of melatonin by heterocyclic skeleton such as 1,4-benzodioxin, 2,3-dihydro-1,4-benzodioxin, chroman, 2,3-dihydro-1,4-benzoxathiin, thiochroman, carrying the amidic chain on the aromatic ring, leads to compounds showing a weak affinity for melatonin receptors, except for the compounds 1cb and 1hb. (C) 2000 Elsevier Science Ltd, All rights reserved.

  DOI：

  10.1016/s0968-0896(99)00265-5

文献信息

• [EN] HETEROCYCLIC COMPOUNDS, METHODS OF MAKING THEM AND THEIR USE IN THERAPY<br/>[FR] COMPOSES HETEROCYCLIQUES, PROCEDES DE PRODUCTION DE CEUX-CI ET UTILISATION DE CEUX-CI DANS UN TRAITEMENT
  申请人：AFFINIUM PHARM INC

  公开号：WO2004052890A1

  公开（公告）日：2004-06-24

  In part, the present invention is directed to antibacterial compounds of formula (I) wherein A is a bicyclic heteroaryl ring or a tricyclic ring and R2 is an heterocyclic residue; L is a bond, or L is alkyl, alkenyl or cycloalkyl.

  在某种程度上，本发明涉及公式（I）的抗菌化合物，其中A是一个双环杂芳基环或三环环，R2是一个杂环残基；L是一个键，或者L是烷基，烯基或环烷基。
• Compositions comprising multiple bioactive agents, and methods of using the same
  申请人：Berman M. Judd

  公开号：US20060142265A1

  公开（公告）日：2006-06-29

  In part, the present invention is directed to compositions comprising a FabI inhibitor and at least one other bioactive agent. In another part, the present invention is directed to antibacterial compositions comprising a compound of formulas I-III and at least one other antibacterial agent.

  本发明的一部分涉及含有FabI抑制剂和至少一种其他生物活性剂的组合物。另一部分，本发明涉及含有I-III式化合物和至少一种其他抗菌剂的抗菌组合物。
• Heterocyclic compounds, methods of making them and their use in therapy
  申请人：Berman Judd

  公开号：US20060183908A1

  公开（公告）日：2006-08-17

  In part, the present invention is directed to antibacterial compounds of formula (I) wherein A is a bicyclic heteroaryl ring or a tricyclic ring and R 2 is an heterocyclic residue; L is a bond, or L is alkyl, alkenyl or cycloalkyl.

  部分地，本发明涉及公式（I）中的抗菌化合物，其中A是双环杂芳基环或三环环，并且R2是杂环残基; L是键合或L是烷基，烯基或环烷基。
• Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine
  申请人：Danysz Wojciech

  公开号：US20080039458A1

  公开（公告）日：2008-02-14

  Substituted pyrazolopyrimidine derivatives of formula (I) wherein Y 1 , Y 2 , Y 3 , Y 4 represent N or C—, whereby at least two of the groups Y 1 to Y 4 represent a carbon atom, R 1 represents chloro or bromo, R 2 to R 7 represent e.g. hydrogen, methyl or ethyl; and R 10 and R 11 independently represent e.g. hydrogen or C 1 -C 6 alkyl, are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.

  式(I)中的取代嘧唑嘧啶衍生物，其中Y1、Y2、Y3、Y4代表N或C—，其中至少两个Y1到Y4代表碳原子，R1代表氯或溴，R2到R7代表氢、甲基或乙基等，而R10和R11独立地代表氢或C1-C6烷基。这些衍生物是有效的mGluR5调节剂，并可用于预防急性和慢性神经系统疾病。
• Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators
  申请人：MERZ PHARMA GmbH & Co. KGaA

  公开号：US07985753B2

  公开（公告）日：2011-07-26

  Substituted pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2, Y3, Y4 represent N or C—, whereby at least two of the groups Y1 to Y4 represent a carbon atom, R1 represents chloro or bromo, R2 to R7 represent e.g. hydrogen, methyl or ethyl; and R10 and R11 independently represent e.g. hydrogen or C1-C6alkyl, are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.

  公式（I）的取代嘧唑嘧啶衍生物，其中Y1、Y2、Y3、Y4代表N或C-，其中至少两个Y1到Y4代表碳原子，R1代表氯或溴，R2到R7代表氢、甲基或乙基等基团，而R10和R11独立地代表氢或C1-C6烷基。这些衍生物是强效的mGluR5调节剂，可用于预防急性和慢性神经系统疾病。